| Trial ID # | NCT02345265 |
| Phase | II |
| Drug Class | DNA Damage Repair Pathway Inhibitors: PARP |
| Drug Name | Olaparib |
| Alternate Drug Names | AZD2281, Lynparza |
| Drugs in Trial | Cediranib, Olaparib |
| Eligible Participant | Recurrent high grade serous or high grade endometrioid ovarian cancer |
| Patients Enrolled | 70, 35 Pt-S; median 2 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Biomarkers | Exploratory: gBRCA1/2 |
| Efficacy | ORR: 74.3% (3CR, 23PR, n=35) Exploratory analysis gBRCA status: |
| Clinically Significant Adverse Events | Grade 3/4 AE: hypertension (18%) |
| Conclusion | Olaparib+cediranib is effective independent of gBRCA status |
| Reference | Liu JF et al. A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). J Clin Oncol (2018) 36 (suppl; abstr 5519) |